

10/502244  
PCT/EP03/01229



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

REC'D 21 MAR 2003

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02075544.3

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

**BEST AVAILABLE COPY**



Anmeldung Nr:  
Application no.: 02075544.3  
Demande no:

Anmelde tag:  
Date of filing: 08.02.02  
Date de dépôt:

## Anmelder/Applicant(s)/Demandeur(s):

Vlaams Interuniversitair Instituut voor  
Biotechnologie vzw.  
Rijvisschestraat 120  
9052 Zwijnaarde  
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

A novel target to inhibit angiogenesis

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K39/00

Am Anmelde tag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

## A novel target to inhibit angiogenesis

### Field of the invention

The invention relates to the field of pathological angiogenesis. In particular the  
5 invention relates to the use of molecules binding to AC133 that can be used for the manufacture of a medicament to prevent angiogenesis.

### Background of the invention

The "hemangioblast" is a putative progenitor cell that has the potential to form either  
10 endothelial or hematopoietic cells. It exists during embryogenesis in the blood island region of the yolk sac (1), which is therefore the earliest site of hematopoiesis and vasculogenesis. Until recently, vasculogenesis has been thought to be restricted to the yolk sac and the early embryogenesis. However, novel observations have revealed in adulthood a situation consistent with vasculogenesis: endothelial cells derived from  
15 angioblasts or "hemangioblasts" previously isolated from peripheral blood or bone marrow are incorporated into sites of neovascularization in physiological and pathological conditions (2-6). In addition, the number of these endothelial cell progenitors increases in the peripheral blood during tissue ischemia or following the administration of VEGF or GM-CSF, a cytokine known to induce mobilization of  
20 hematopoietic stem cells from the bone marrow into the peripheral blood (5, 6). Recent studies in humans, dogs, rats, rabbits and mice have indeed indicated the presence of endothelial precursor cells (EPCs) in bone marrow and peripheral blood during adult life which can be mobilized and incorporated into newly formed vessels or are involved in endothelialization of implants (4, 7-13). Interestingly, in all these  
25 experiments, EPCs are isolated together with other hematopoietic stem cells by using antibodies directed against hematopoietic stem cell antigens. AC133 is a rather novel human hematopoietic stem cell antigen (14) of unknown physiological or pathological function. AC133, recently designed CD133 (National Center for Biotechnology, 2000)  
is expressed on lineage non-committed stem and progenitor cells but not on mature  
30 peripheral blood cells and umbilical vein derived endothelial cells (15). It is detected on 30-60% of all CD34<sup>+</sup> cells, including CD34<sup>bright</sup> cells. This cell population contains CD38<sup>dim/neg</sup>, HLA-DR<sup>+</sup>, CD117<sup>+</sup>, CD90<sup>+</sup> cells. AC133<sup>+</sup> CD34<sup>+</sup> hematopoietic stem cells

are enriched in Long-Term Culture-Initiating Cells, NOD/SCID repopulating cells and dendritic cell progenitors (16). Subsets of this population express the angiopoietin receptors TIE (67.6%) and TEK (36.8%), Flt-1 (7%), Flt-4 (3.2%), KDR (10.4%), the receptor tyrosine kinase HER-2 (15.4%) and Flt-3 (77.6%). Only few AC133<sup>+</sup> cells do  
5 not co-express CD34: these cells are very small and define a population of unknown delineation (CD71<sup>+</sup>, CD117<sup>+</sup>, CD10<sup>+</sup>, CD38<sup>low</sup>, CD135<sup>+</sup>, HLA-DR<sup>high</sup>) (17). In acute myeloid leukemias, AC133 expression is often but not always associated with CD34 expression (18, 19). AC133 is also found on acute lymphoid leukemia blasts and on a subset of CD34<sup>+</sup> B-cell precursors (20). Flow cytometric analyses of a wide panel of  
10 human cell lines showed that only retinoblastoma and teratocarcinoma cell lines express AC133 (21). Recently, AC133 was found to be expressed in EPCs. CD34<sup>+</sup> cells co-expressing VEGFR-2 and AC133 have been isolated from peripheral blood, cord blood, fetal liver and bone marrow. However, the possible role of AC 133 in hematopoiesis and vasculogenesis in the developing embryo and, after birth, in  
15 angiogenesis, postnatal vasculogenesis and hematopoietic stem cell trafficking, remains largely unknown. To study in detail the *in vivo* role of AC133 in the present invention AC133 deficient mice were generated. It was surprisingly found that AC 133 has a key role in pathological vasculogenesis and/or angiogenesis and that inhibitors of AC133 can be used in therapeutic strategies to inhibit blood vessel formation in  
20 various pathological disorders.

#### Aims and detailed description of the invention

AC133 is a protein of 97 KD with a 5-transmembrane structure (14). The 5-transmembrane structure appears at present restricted to the human AC133, the  
25 murine prominin and the related protein of the nematode C. elegans (25-28). This structure indicates that these proteins belong to a new class of serpentine receptors. Murine prominin has 60% amino acid homology with AC133 (25). It is not yet clear whether murine prominin is the murine homologue of human AC133, or whether it is a close family member (25, 26). For the sake of clarity the nucleotide sequence of  
30 human AC133 is designated here as SEQ ID NO: 1 and the amino acid sequence of human AC133 is designated as SEQ ID NO: 2. The present invention shows that inhibitors of AC133 can be used in therapeutic applications for the prevention of pathological angiogenesis.

Thus the invention provides in one embodiment the use of a molecule which comprises a region specifically binding to AC133 or nucleic acids encoding AC133, for the manufacture of a medicament to treat pathological angiogenesis.

- 5 According to the invention molecules that comprise a region specifically binding to AC133 or nucleic acids encoding AC133 which can be used for the manufacture of a medicament to treat pathological angiogenesis can be chosen from the list comprising an antibody or any fragment thereof binding to AC133, a (synthetic) peptide, a protein, a small molecule specifically binding to AC133 or nucleic acids encoding AC133, a  
10 ribozyme against nucleic acids encoding AC133, and anti-sense nucleic acids hybridising with nucleic acids encoding AC133.

The term 'antibody' or 'antibodies' relates to an antibody characterized as being specifically directed against AC133 or any functional derivative thereof, with said  
15 antibodies being preferably monoclonal antibodies; or an antigen-binding fragment thereof, of the F(ab')<sub>2</sub>, F(ab) or single chain Fv type, or any type of recombinant antibody derived thereof. These antibodies of the invention, including specific polyclonal antisera prepared against AC133 or any functional derivative thereof, have no cross-reactivity to others proteins. The monoclonal antibodies of the Invention can  
20 for instance be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly of a mouse or rat immunized against AC133 or any functional derivative thereof, and of cells of a myeloma cell line, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing AC133 or any functional derivative thereof which have been  
25 initially used for the immunization of the animals. The monoclonal antibodies according to this embodiment of the invention may be humanized versions of the mouse monoclonal antibodies made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains. Alternatively the monoclonal  
30 antibodies according to this embodiment of the invention may be human monoclonal antibodies. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice as described in PCT/EP 99/03605 or by using transgenic non-human animals capable of producing human antibodies as described

in US patent 5,545,806. Also fragments derived from these monoclonal antibodies such as Fab, F(ab)<sub>2</sub> and ssFv ("single chain variable fragment"), providing they have retained the original binding properties, form part of the present invention. Such fragments are commonly generated by, for instance, enzymatic digestion of the 5 antibodies with papain, pepsin, or other proteases. It is well known to the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses. The antibodies involved in the invention can be labeled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

In a specific embodiment the antibodies against AC133 can be derived from animals 10 of the camelid family. In said family immunoglobulins devoid of light polypeptide chains are found. Heavy chain variable domain sequences derived from camelids are designated as VHH's. "Camelids" comprise old world camelids (*Camelus bactrianus* and *Camelus dromaderius*) and new world camelids (for example *Lama pacos*, *Lama glama* and *Lama vicugna*). EP0656946 describes the isolation and uses of camelid 15 immunoglobulins and is incorporated herein by reference.

Small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries.

Also within the scope of the invention are oligoribonucleotide sequences, that include 20 anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of AC133 mRNA. Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. In regard to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between -10 and +10 regions of the AC133 nucleotide 25 sequence, are preferred. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently 30 catalyze endonucleolytic cleavage of AC133 RNA sequences.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of

between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to 5 hybridization with complementary oligonucleotides, using ribonuclease protection assays.

Both anti-sense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in 10 the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase 15 promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize anti-sense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

The term 'pathological angiogenesis' refers to the formation and growth of blood vessels during the maintenance and the progression of several disease states. 20 Examples where pathological angiogenesis can occur are blood vessels (atherosclerosis, hemangioma, hemangioendothelioma), bone and joints (rheumatoid arthritis, synovitis, bone and cartilage destruction, osteomyelitis, pannus growth, osteophyte formation, neoplasms and metastasis), skin (warts, pyogenic granulomas, hair growth, Kaposi's sarcoma, scar keloids, allergic oedema, neoplasms), liver, 25 kidney, lung, ear and other epithelia (inflammatory and infectious processes (including hepatitis, glomerulonephritis, pneumonia), asthma, nasal polyps, otitis, transplantation, liver regeneration, neoplasms and metastasis), uterus, ovary and placenta (dysfunctional uterine bleeding (due to intrauterine contraceptive devices), follicular cyst formation, ovarian hyperstimulation syndrome, endometriosis, neoplasms), brain, 30 nerves and eye (retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, leukomalacia, neoplasms and metastasis), heart and skeletal muscle due to work overload, adipose tissue (obesity), endocrine organs (thyroiditis, thyroid enlargement, pancreas transplantation), hematopoiesis (AIDS (Kaposi),

hematologic malignancies (leukemias, etc.), lymph vessels (tumour metastasis, lymphoproliferative disorders).

The term 'medicament to treat' relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above. Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives. Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers. The 'medicament' may be administered by any suitable method within the knowledge of the skilled man. The preferred route of administration is parenterally. In parental administration, the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. However, the dosage and mode of administration will depend on the individual. Generally, the medicament is administered so that the protein, polypeptide, peptide of the present invention is given at a dose between 1 µg/kg and 10 mg/kg, more preferably between 10 µg/kg and 5 mg/kg, most preferably between 0.1 and 2 mg/kg. Preferably, it is given as a bolus dose. Continuous infusion may also be used and includes continuous subcutaneous delivery via an osmotic minipump. If so, the medicament may be infused at a dose between 5 and 20 µg/kg/minute, more preferably between 7 and 15 µg/kg/minute.

In another embodiment antibodies or functional fragments thereof can be used for the manufacture of a medicament for the treatment of the above mentioned disorders. As a non-limiting example there are the antibodies described in US 5,843,633. In a specific embodiment said antibodies are humanized (Rader et al., 2000, J. Biol. Chem. 275, 13688) and more specifically human antibodies are used to manufacture a medicament to treat pathological angiogenesis. In yet another specific embodiment antibodies derived from camelids are used to manufacture a medicament to treat pathological angiogenesis.

Another aspect of administration for treatment is the use of gene therapy to deliver the above mentioned anti-sense gene or functional parts of the AC133 gene or a ribozyme directed against the AC133 mRNA or a functional part thereof. Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells. This is 5 extensively reviewed in Lever and Goodfellow 1995; Br. Med Bull., 51, 1-242; Culver 1995; Ledley, F.D. 1995. Hum. Gene Ther. 6, 1129. To achieve gene therapy there must be a method of delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes. There are two general approaches to achieve gene delivery; these are non-viral delivery and virus-mediated 10 gene delivery.

The invention also provides methods for identifying compounds or molecules which bind on AC133 and prevent or suppress pathological angiogenesis. With "suppression" it is understood that said suppression can occur for at least 20%, 30%, 15 30%, 50%, 60%, 70%, 80%, 90% or even 100%.

Thus in another embodiment the invention provides a method to identify molecules that comprise a region that specifically binds to AC133 comprising: (1) exposing AC133 or nucleic acids encoding AC133 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined, (2) determining binding or hybridising of said molecule(s) to AC133 or nucleic acids encoding AC133, and (3) monitoring said pathological angiogenesis when administering said molecules as a medicament.

The latter method is also referred to as 'drug screening assay' or 'bioassay' and typically include the step of screening a candidate/test compound or agent for the 25 ability to interact with AC133. Candidate compounds or agents, which have this ability, can be used as drugs to combat or prevent pathological conditions of angiogenesis. Candidate/test compounds such as small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries as described above.

30 Typically, the assays are cell-free assays which include the steps of combining AC133 and a candidate/test compound, e.g., under conditions which allow for interaction of (e.g. binding of) the candidate/test compound with AC133 to form a complex, and detecting the formation of a complex, in which the ability of the candidate compound to

interact with AC133 is indicated by the presence of the candidate compound in the complex. Formation of complexes between AC133 and the candidate compound can be quantitated, for example, using standard immunoassays. The AC133 employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located extracellularly or even intracellularly.

To perform the above described drug screening assays, it is feasible to immobilize AC133 or its (their) target molecule(s) to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Interaction (e.g., binding of) of AC133 to a target molecule, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and microcentrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, AC133-His tagged can be adsorbed onto Ni-NTA microtitre plates, or AC133-ProtA fusions adsorbed to IgG, which are then combined with the cell lysates (e.g., <sup>35</sup>S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the plates are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of AC133-binding protein found in the bead fraction quantitated from the gel using standard electrophoretic techniques. Other techniques for immobilizing protein on matrices can also be used in the drug screening assays of the invention. For example, AC133 can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated AC133 can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Another technique for drug screening which provides for high throughput screening of compounds having suitable binding affinity to AC133 is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO 84/03564, published on 13/09/84. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The protein test compounds are reacted with fragments of AC133 and washed. Bound AC133 is then detected by methods well known in the art. Purified

AC133 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. This invention also contemplates the use of competitive drug screening assays in which neutralizing 5 antibodies capable of binding AC133 specifically compete with a test compound for binding AC133. In this manner, the antibodies can be used to detect the presence of any protein, which shares one or more antigenic determinants with AC133.

### Examples

#### 10 1. Generation of a AC133 knock-out mouse

Targeted inactivation of the AC133 gene was achieved by deletion of exon 2 (containing the start codon). Briefly, a genomic BAC (bacterial artificial chromosome) containing the murine AC133 (14) was obtained from Research Genetics Inc (Huntsville, AL) after screening by PCR and hybridization. Mapping of the murine 15 AC133 homologue gene revealed that the first exon, which is 79 bp long, is separated from the second exon by an approximately 8 kb intron. It is the second exon (376 bp long) which contains the startcodon ATG. A BamHI fragment of 11.5 kb containing exon 2 was subcloned into the pUC18 plasmid. A targeting vector for inactivation of the AC133 gene, pPNT.AC133<sup>null</sup>, was constructed consisting of, from 5' to 3': 1.2 kb 20 of 5' homology comprising the end of intron 1; a loxP-flanked neomycin gene; 5.5 kb from intron 2 as 3'-homology; and a thymidine kinase selection cassette outside of the regions of homology for counterselection against random integration events. The integrity of the construct was verified by restriction digestion and sequencing. The linearized targeting vector pPNT.AC133<sup>null</sup> was electroporated in R1 ES cells and 25 targeted clones were identified by appropriate Southern blot analysis and used for morula aggregation to generate AC133 deficient chimeric and germline mice. AC133<sup>-/-</sup> mice were born at the expected Mendelian frequency (~25% of 450 offspring from AC133<sup>+/+</sup> breeding pairs). They appeared healthy and were fertile, irrespective of their genetic background (backgrounds tested: 50% Swiss/50% 129, 100% 129, 50% 30 C57Bl6/50% 129 and 50% NMRI/50% 129). We anticipated that AC133 might play a crucial role in hematopoiesis implying that the AC133<sup>-/-</sup> embryo would die *in utero* either after the appearance of the primitive hematopoiesis (7.5 days post coitum, site:

yolk sac) or at the emergence of the definitive hematopoiesis (12.5 days post coitum, site: fetal liver). Surprisingly, however, embryonic development in AC133<sup>-/-</sup> mice was normal. AC133<sup>-/-</sup> embryos were not rescued by maternal AC133, as AC133<sup>-/-</sup> embryos, sired by AC133<sup>+/+</sup> as well as by AC133<sup>-/-</sup> breeding pairs, developed normally. Also 5 postnatal physiological vascular development seemed normal since no vascular defects could be observed in the heart, kidneys, lungs and skeletal muscle during postnatal growth in AC133<sup>-/-</sup> mice.

## 2. Impaired pathological angiogenesis in AC133 knock-out mice

10 In order to study the possible role of AC133 in pathological conditions of angiogenesis AC 133<sup>-/-</sup> mice and their wild-type littermates were subjected to a mouse model of ischemic retinopathy. In this hyperoxia-induced retinopathy model, neonatal mice (with an immature retinal vasculature) are exposed to hyperoxia, resulting in obliteration of the developing blood vessels supplying oxygen to the retina. When the mice are then 15 returned to normoxia, the retina, distal to the occluded vessels, becomes ischemic, inducing VEGF production and ultimately resulting in reproducible and quantifiable proliferative retinal neovascularization (29, 30). This model, which mimicks to a certain extent the vascular response during retinopathy of prematurity or diabetic retinopathy, may be useful to test the efficacy of (anti)-angiogenic molecules (31). Mouse pups of 7 20 days (P7) together with their mothers, are subjected to hyperoxia (75% oxygen) in specially designed oxygen chambers for 5 days, without opening the cages. On P12, the animals are returned to room air until P17, when the retinas are assessed for maximal neovascular response. Anesthetized mice are perfused through the left ventricle with 1 ml of phosphate buffered saline containing 50 mg of 2x10<sup>6</sup> molecular 25 weight fluorescein-dextran. The eyes are removed and fixed in 4% paraformaldehyde for 3 (right eye) or 24 (left eye) hrs. Of the right eyes, lenses are removed and peripheral retinas cut to allow flat mounting with glycerol-gelatin. The flat mounted retinas are analyzed by fluorescence microscopy. The left eyes are embedded in paraffin and serial 6 µm sections are cut sagittally throughout the cornea, parallel to 30 the optic nerve, and stained with hematoxylin-eosin. The proliferative neovascular response is quantified by counting the number of new vessels (= tufts) and the number of endothelial cells extending from the internal limiting membrane of the retina into the vitreum on the stained sagittal cross-sections. The angiographic technique using

fluorescein-dextran perfusion is used in conjunction with this counting method for rapid screening of retinas or as an alternative grading system for quantitative evaluation.

Loss of AC133 significantly protected mice against intra-vitreous neovascularization, as evaluated by counting the number of neovascular tufts and endothelial cells (EC) in

5 the vitreous cavity (n=15; p<0.001)

	N° of tufts in vitreous cavity (per 10 retinal sections)	N° of EC in vitreous cavity (per 10 retinal sections)
AC133 <sup>+/+</sup> pups (n = 15)	157.1 ± 13.6	286.0 ± 45.1
AC133 <sup>-/-</sup> pups (n = 15)	72.5 ± 14.6	106.2 ± 22.6

10

15

20

References

1. Risau W. Mechanisms of angiogenesis. *Nature* 1997;386(6626):671-4.
2. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. *Science* 1997;275(5302):964-7.
3. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, et al. Evidence for circulating bone marrow-derived endothelial cells. *Blood* 1998;92(2):362-7.
4. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. *Nat Med* 1999;5(4):434-8.
5. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. *Circ Res* 1999;85(3):221-8.
- 15 6. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. *Embo J* 1999;18(14):3964-72.
7. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, et al. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. *Blood* 2000;95(2):581-5.
- 20 8. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. *Proc Natl Acad Sci U S A* 2000;97(7):3422-7.
9. Schatterman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived 25 angioblasts accelerate blood-flow restoration in diabetic mice. *J Clin Invest* 2000;106(4):571-8.
10. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. *Circulation* 2001;103(5):634-7.
- 30 11. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001;7(4):430-6.

12. Vasa M, Fichtlscher S, Aicher A, Adler K, Urbich C, Manhart H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 2001;89(1):E1-7.
- 5 13. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. *Circ Res* 2001;88(2):167-74.
- 10 14. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. *Blood* 1997;90(12):5013-21.
- 15 15. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. *Blood* 1997;90(12):5002-12.
- 20 16. de Wynter EA, Buck D, Hart C, Heywood R, Coutinho LH, Clayton A, et al. CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors. *Stem Cells* 1998;16(6):387-96.
- 25 17. Buhring HJ, Seiffert M, Bock TA, Scheding S, Thiel A, Scheffold A, et al. Expression of novel surface antigens on early hematopoietic cells. *Ann NY Acad Sci* 1999;872:25-38; discussion 38-9.
- 30 18. Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D. Expression of AC133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. *Blood* 1999;93(4):1435-7.
19. Kratz-Albers K, Zuhlsdorf M, Leo R, Berdel WL, Buchner T, Serve H. Expression of a AC133, a novel stem cell marker, on human leukemic blasts lacking CD34- antigen and on a human CD34+ leukemic line: MUTZ-2. *Blood* 1998;92(11):4485-7.
20. Buhring HJ, Seiffert M, Marxer A, Weiss B, Faul C, Kanz L, et al. AC133 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. *Blood* 1999;94(2):832-3.
21. Corbeil D, Roper K, Hannah MJ, Hellwig A, Huttner WB. Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells - a combination of apical sorting and retention in plasma membrane protrusions. *J Cell Sci* 1999;112(Pt 7):1023-33.

22. Gehling UM, Erg S, Schumacher U, Wagener C, Pantel K, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. *Blood* 2000;95(10):3106-12.
- 5 23. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. *Blood* 2000;95(3):952-8.
24. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. *Br J Haematol* 2001;115(1):186-94.
- 10 25. Corbeil D, Roper K, Weigmann A, Huttner WB. AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(7):2625-6.
- 15 26. Miraglia S, Godfrey W, Buck D. A response to AC133 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? *Blood* 1998;91(11):4390-1.
27. Wilson R, Ainscough R, Anderson K, Baynes C, Berks M, Bonfield J, et al. 2.2 Mb of contiguous nucleotide sequence from chromosome III of *C. elegans*. *Nature* 1994;368(6466):32-8.
- 20 28. Weigmann A, Corbell D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. *Proc Natl Acad Sci U S A* 1997;94(23):12425-30.
- 25 29. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):101-11.
- 30 30. Wesolowski E, Smith LE. Effect of light on oxygen-induced retinopathy in the mouse. *Invest Ophthalmol Vis Sci* 1994;35(1):112-9.
31. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. *Proc Natl Acad Sci U S A* 1995;92(3):905-9.

Claims

1. Use of a molecule which comprises a region specifically binding to AC133 or nucleic acids encoding AC133, for the manufacture of a medicament to treat pathological angiogenesis.  
5
2. Use according to claim 1 wherein said molecule is chosen from the list comprising an antibody or any fragment thereof binding to AC133, a small molecule specifically binding to AC133 or nucleic acids encoding AC133, a ribozyme against nucleic acids encoding AC133, and anti-sense nucleic acids hybridising with nucleic acids encoding AC133.  
10
3. A method to identify molecules that comprise a region that specifically binds to AC133 comprising:  
15
  - exposing AC133 or nucleic acids encoding AC133 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined,
  - determining binding or hybridising of said molecule(s) to AC133 or nucleic acids encoding AC133, and
  - monitoring said pathological angiogenesis when administering said molecules as a medicament.  
20

25

30

Abstract

The invention relates to the field of pathological angiogenesis. In particular the invention relates to the use of molecules binding to AC133 that can be used for the manufacture of a medicament to prevent angiogenesis.

5

Untitled.ST25.txt  
SEQUENCE LISTING

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW  
<120> A NOVEL TARGET TO INHIBIT ANGIOGENESIS  
<130> PCA/AC133/111  
<160> 2  
<170> PatentIn version 3.1  
<210> 1  
<211> 3794  
<212> DNA  
<213> HOMO sapiens  
  
<220>  
<221> CDS  
<222> (38) .. (2635)  
<223>

## Untitled.ST25.txt

ata ata ata agc att ggc atc ttc tat ggt ttt gtg gca aat cac cag Ile Ile Ile Ser Ile Gly Ile Phe Tyr Gly Phe Val Ala Asn His Gln 170 175 180	583
gta aga acc cgg atc aaa agg agt cgg aaa ctg gca gat agc aat ttc Val Arg Thr Arg Ile Lys Arg Ser Arg Lys Leu Ala Asp Ser Asn Phe 185 190 195	631
aag gac ttg cga act ctc ttg aat gaa act cca gag caa atc aaa tat Lys Asp Leu Arg Thr Leu Leu Asn Glu Thr Pro Glu Gln Ile Lys Tyr 200 205 210	679
ata ttg gcc cag tac aac act acc aag gac aag gcg ttc aca gat ctg Ile Leu Ala Gln Tyr Asn Thr Thr Lys Asp Lys Ala Phe Thr Asp Leu 215 220 225 230	727
aac agt atc aat tca gtg cta gga ggc gga att ctt gac cga ctg aga Asn Ser Ile Asn Ser Val Leu Gly Gly Ile Leu Asp Arg Leu Arg 235 240 245	775
ccc aac atc atc cct gtt ctt gat gag att aag tcc atg gca aca gcg Pro Asn Ile Ile Pro Val Leu Asp Glu Ile Lys Ser Met Ala Thr Ala 250 255 260	823
atc aag gag acc aaa gag gcg ttg gag aac atg aac agc acc ttg aag Ile Lys Glu Thr Lys Glu Ala Leu Glu Asn Met Asn Ser Thr Leu Lys 265 270 275	871
agc ttg cac caa caa agt aca cag ctt agc agc agt ctg acc agc gtc Ser Leu His Gln Gln Ser Thr Gln Leu Ser Ser Leu Thr Ser Val 280 285 290	919
aaa act agc ctg cgg tca tct ctc aat gac cct ctg tgc ttg gtc cat Lys Thr Ser Leu Arg Ser Ser Leu Asn Asp Pro Leu Cys Leu Val His 295 300 305 310	967
cca tca agt gaa acc tgc aac agc atc aga ttg tct cta agc cag ctg Pro Ser Ser Glu Thr Cys Asn Ser Ile Arg Leu Ser Leu Ser Gln Leu 315 320 325	1015
aat agc aac cct gaa ctg agg cag ctt cca ccc gtc gat gca gaa ctt Asn Ser Asn Pro Glu Leu Arg Gln Leu Pro Pro Val Asp Ala Glu Leu 330 335 340	1063
gac aac gtt aat aac gtt ctt agg aca gat ttg gat ggc ctg gtc caa Asp Asn Val Asn Asn Val Leu Arg Thr Asp Leu Asp Gly Leu Val Gln 345 350 355	1111
cag ggc tat caa tcc ctt aat gat ata cct gac aga gta caa cgc caa Gln Gly Tyr Gln Ser Leu Asn Asp Ile Pro Asp Arg Val Gln Arg Gln 360 365 370	1159
acc acg act gtc gta gca ggt atc aaa agg gtc ttg aat tcc att ggt Thr Thr Thr Val Val Ala Gly Ile Lys Arg Val Leu Asn Ser Ile Gly 375 380 385 390	1207
tca gat atc gac aat gta act cag cgt ctt cct att cag gat ata ctc Ser Asp Ile Asp Asn Val Thr Gln Arg Leu Pro Ile Gln Asp Ile Leu 395 400 405	1255
tca gca ttc tct gtt tat gtt aat aac act gaa agt tac atc cac aga Ser Ala Phe Ser Val Tyr Val Asn Asn Thr Glu Ser Tyr Ile His Arg 410 415 420	1303
aat tta cct aca ttg gaa gag tat gat tca tac tgg tgg ctg ggt ggc Asn Leu Pro Thr Leu Glu Glu Tyr Asp Ser Tyr Trp Trp Leu Gly Gly 425 430 435	1351

## Untitled.ST25.txt

ctg gtc atc tgc tct ctg ctg acc ctc atc gtg att ttt tac tac tac ctg Leu Val Ile Cys Ser Leu Leu Thr Leu Ile Val Ile Phe Tyr Tyr Leu 440 445 450	1399
ggc tta ctg tgt ggc gtg tgc ggc tat gac agg cat gcc acc ccg acc Gly Leu Leu Cys Gly Val Cys Gly Tyr Asp Arg His Ala Thr Pro Thr 455 460 465 470	1447
acc cga ggc tgt gtc tcc aac acc gga ggc gtc ttc ctc atg gtt gga Thr Arg Gly Cys Val Ser Asn Thr Gly Val Phe Leu Met Val Gly 475 480 485	1495
gtt gga tta agt ttc ctc ttt tgc tgg ata ttg atg atc att gtg gtt Val Gly Leu Ser Phe Leu Phe Cys Trp Ile Leu Met Ile Ile Val Val 490 495 500	1543
ctt acc ttt gtc ttt ggt gca aat gtg gaa aaa ctg atc tgt gaa act Leu Thr Phe Val Phe Gly Ala Asn Val Glu Lys Leu Ile Cys Glu Pro 505 510 515	1591
tac acg agc aag gaa tta ttc cgg gtt ttg gat aca ccc tac tta cta Tyr Thr Ser Lys Glu Leu Phe Arg Val Leu Asp Thr Pro Tyr Leu Leu 520 525 530	1639
aat gaa gac tgg gaa tac tat ctc tat ggg aag cta ttt aat aaa tca Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly Lys Leu Phe Asn Lys Ser 535 540 545 550	1687
aaa atg aag ctc act ttt gaa caa gtt tac agt gac tgc aaa aaa aat Lys Met Lys Leu Thr Phe Glu Gln Val Tyr Ser Asp Cys Lys Lys Asn 555 560 565	1735
aga ggc act tac ggc act ctt cac ctg cag aac agc ttc aat atc agt Arg Gly Thr Tyr Gly Thr Leu His Leu Gln Asn Ser Phe Asn Ile Ser 570 575 580	1783
gaa cat ctc aac att aat gag cat act gga agc ata agc agt gaa ttg Glu His Leu Asn Ile Asn Glu His Thr Gly Ser Ile Ser Ser Glu Leu 585 590 595	1831
gaa agt ctg aag gta aat ctt aat atc ttt ctg ttg ggt gca gca gga Glu Ser Leu Ilys Val Asn Leu Asn Ile Phe Leu Leu Gly Ala Ala Gly 600 605 610	1879
aga aaa aac ctt cag gat ttt gct gct tgt gga ata gac aga atg aat Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys Gly Ile Asp Arg Met Asn 615 620 625 630	1927
tat gac agc tac ttg gct cag act ggt aaa tcc ccc gca gga gtg aat Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys Ser Pro Ala Gly Val Asn 635 640 645	1975
ctt tta tca ttt gca tat gat cta gaa gca aaa gca aac agt ttg ccc Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala Lys Ala Asn Ser Leu Pro 650 655 660	2023
cca gga aat ttg agg aac tcc ctg aaa aga gat gca caa act att aaa Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg Asp Ala Gln Thr Ile Lys 665 670 675	2071
aca att cac cag caa cga gtc ctt cct ata gaa caa tca ctg agc act Thr Ile His Gln Gln Arg Val Leu Pro Ile Glu Gln Ser Leu Ser Thr 680 685 690	2119
cta tac caa agc gtc aag ata ctt caa cgc aca ggg aat gga ttg ttg Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg Thr Gly Asn Gly Leu Leu 695 700 705 710	2167

## Untitled.ST25.txt

gag aga gta act agg att cta gct tct ctg gat ttt gct gag aac ttc Glu Arg Val Thr Arg Ile Leu Ala Ser Leu Asp Phe Ala Gln Asn Phe 715 720 725	2215
atc aca aac aat act tcc tct gtt att att gag gaa act aag aag tat Ile Thr Asn Asn Thr Ser Ser Val Ile Ile Glu Glu Thr Lys Lys Tyr 730 735 740	2263
ggg aga aca ata ata gga tat ttt gaa cat tat ctg cag tgg atc gag Gly Arg Thr Ile Ile Gly Tyr Phe Glu His Tyr Leu Gln Trp Ile Glu 745 750 755	2311
tcc tct atc agt gag aaa gtg gca tcg tgc aaa cct gtg gcc acc gct Phe Ser Ile Ser Glu Lys Val Ala Ser Cys Lys Pro Val Ala Thr Ala 760 765 770	2359
cta gat act gct gtt gat gtc ttt ctg tgt agc tac att atc gac ccc Leu Asp Thr Ala Val Asp Val Phe Leu Cys Ser Tyr Ile Ile Asp Pro 775 780 785 790	2407
ttg aat ttg ttt tgg ttt ggc ata gga aaa gct act gta ttt tta ctt Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys Ala Thr Val Phe Leu Leu 795 800 805	2455
ccg gct cta att ttt gcg gta aaa ctg gct aag tac tat cgt cga atg Pro Ala Leu Ile Phe Ala Val Lys Leu Ala Lys Tyr Tyr Arg Arg Met 810 815 820	2503
gat tcg gag gac gtg tac gat gat gtt gaa act ata ccc atg aaa aat Asp Ser Glu Asp Val Tyr Asp Asp Val Glu Thr Ile Pro Met Lys Asn 825 830 835	2551
atg gaa aat ggt aat aat ggt tat cat aaa gat cat gta tat ggt att Met Glu Asn Gly Asn Asn Gly Tyr His Lys Asp His Val Tyr Gly Ile 840 845 850	2599
cac aat cct gtt atg aca agc cca tca caa cat tga tagctgtatgt His Asn Pro Val Met Thr Ser Pro Ser Gln His 855 860 865	2645
tgaaactgct tgagcatcag gatactcaaa gtggaaagga tcaacagattt ttggtagttt	2705
ctgggtctac aaggacttcc caaatccagg agcaacgcca gtggcaacgt agtgactcag	2765
gcgggcacca aggcaacggc accattggtc tctgggtagt gctttaaagaa tgaacacaat	2825
cacgttatag tccatggtcc atcaatattc aaggatgact ccctcccttc ctgtctat	2885
ttgtttttta ctttttaca ctgagttct attttagacac tacaacatat gggtgttgg	2945
ttccccattgg atgcatttct atcaaaaactc tatcaaatgt gatggctaga ttctaacata	3005
ttgcccattgtg tggagtgtgc tgaacacaca ccagtttaca ggaaagatgc attttgtgt	3065
cagtaaaacgg tgtatataacc ttttgttacc acagagtttt taaaacaaaat gagtattata	3125
ggactttctt ctaaatgagc taaataagtc accattgact tcttggtgct gttgaaaata	3185
atccattttt actaaaaagtg tgtgaaaacct acagcatatt ctccacgcag agatttcat	3245
ctattataact ttatcaaaga ttggccatgt tccacttggaa atggcatgc aaaagccatc	3305
atagagaaaac ctgdgtact ccatctgaca aattcaaaag agagagagag atcttgagag	3365
agaaaatgctg ttctgttcaaa agtggagttg ttttaacaga tgccaattac ggtgtacagt	3425
ttaacagagt ttctgttgc attaggataa acattaattg gagtgccagct aacatgagta	3485

Untitled.ST25.txt

tcatcagact agtatcaagt gttataaaat gaaatatgag aagatccgt cacaatttt	3545
agatctggtg tccagcatgg atgaaacctt tgagtttgtt ccctaaatcc gcatgaaagc	3605
acaaggtaaa tattcatttt cttcaggagt ttcatgttgg atctgtcatt atcaaaaatgt	3665
atcagcaatg aagaactggt cggacaaaat ttaacgttga tgtaatggaa ttccagatgt	3725
aggcattccc cccaggtctt ttcatgtgca gattgcagtt ctgattcatt tgaataaaaa	3785
ggaacttgg	3794

<210> 2  
<211> 865  
<212> PRT  
<213> Homo sapiens

<400> 2

Met Ala Leu Val Leu Gly Ser Leu Leu Leu Leu Gly Leu Cys Gly Asn  
1 5 10 15

Ser Phe Ser Gly Gly Gln Pro Ser Ser Thr Asp Ala Pro Lys Ala Trp  
20 25 30

Asn Tyr Glu Leu Pro Ala Thr Asn Tyr Glu Thr Gln Asp Ser His Lys  
35 40 45

Ala Gly Pro Ile Gly Ile Leu Phe Glu Leu Val His Ile Phe Leu Tyr  
50 55 60

Val Val Gln Pro Arg Asp Phe Pro Glu Asp Thr Leu Arg Lys Phe Leu  
65 70 75 80

Gln Lys Ala Tyr Glu Ser Lys Ile Asp Tyr Asp Lys Pro Glu Thr Val  
85 90 95

Ile Leu Gly Leu Lys Ile Val Tyr Tyr Glu Ala Gly Ile Ile Leu Cys  
100 105 110

Cys Val Leu Gly Leu Leu Phe Ile Ile Leu Met Pro Leu Val Gly Tyr  
115 120 125

Phe Phe Cys Met Cys Arg Cys Cys Asn Lys Cys Gly Gly Glu Met His  
130 135 140

Gln Arg Gln Lys Glu Asn Gly Pro Phe Leu Arg Lys Cys Phe Ala Ile  
145 150 155 160

Ser Leu Leu Val Ile Cys Ile Ile Ile Ser Ile Gly Ile Phe Tyr Gly  
165 170 175

Phe Val Ala Asn His Gln Val Arg Thr Arg Ile Lys Arg Ser Arg Lys  
180 185 190

## Untitled.ST25.txt

Leu Ala Asp Ser Asn Phe Lys Asp Leu Arg Thr Leu Leu Asn Glu Thr  
 195 200 205

Pro Glu Gln Ile Lys Tyr Ile Leu Ala Gln Tyr Asn Thr Thr Lys Asp  
 210 215 220

Lys Ala Phe Thr Asp Leu Asn Ser Ile Asn Ser Val Leu Gly Gly  
 225 230 235 240

Ile Leu Asp Arg Leu Arg Pro Asn Ile Ile Pro Val Leu Asp Glu Ile  
 245 250 255

Lys Ser Met Ala Thr Ala Ile Lys Glu Thr Lys Glu Ala Leu Glu Asn  
 260 265 270

Met Asn Ser Thr Leu Lys Ser Leu His Gln Gln Ser Thr Gln Leu Ser  
 275 280 285

Ser Ser Leu Thr Ser Val Lys Thr Ser Leu Arg Ser Ser Leu Asn Asp  
 290 295 300

Pro Leu Cys Leu Val His Pro Ser Ser Glu Thr Cys Asn Ser Ile Arg  
 305 310 315 320

Leu Ser Leu Ser Gln Leu Asn Ser Asn Pro Glu Leu Arg Gln Leu Pro  
 325 330 335

Pro Val Asp Ala Glu Leu Asp Asn Val Asn Asn Val Leu Arg Thr Asp  
 340 345 350

Leu Asp Gly Leu Val Gln Gln Gly Tyr Gln Ser Leu Asn Asp Ile Pro  
 355 360 365

Asp Arg Val Gln Arg Gln Thr Thr Val Val Ala Gly Ile Lys Arg  
 370 375 380

Val Leu Asn Ser Ile Gly Ser Asp Ile Asp Asn Val Thr Gln Arg Leu  
 385 390 395 400

Pro Ile Gln Asp Ile Leu Ser Ala Phe Ser Val Tyr Val Asn Asn Thr  
 405 410 415

Glu Ser Tyr Ile His Arg Asn Leu Pro Thr Leu Glu Glu Tyr Asp Ser  
 420 425 430

Tyr Trp Trp Leu Gly Gly Leu Val Ile Cys Ser Leu Leu Thr Leu Ile  
 435 440 445

Val Ile Phe Tyr Tyr Leu Gly Leu Leu Cys Gly Val Cys Gly Tyr Asp  
 450 455 460

## Untitled.ST25.txt

Arg His Ala Thr Pro Thr Thr Arg Gly Cys Val Ser Asn Thr Gly Gly  
 465 470 475 480

Val Phe Leu Met Val Gly Val Gly Leu Ser Phe Leu Phe Cys Trp Ile  
 485 490 495

Leu Met Ile Ile Val Val Leu Thr Phe Val Phe Gly Ala Asn Val Glu  
 500 505 510

Lys Leu Ile Cys Glu Pro Tyr Thr Ser Lys Glu Leu Phe Arg Val Leu  
 515 520 525

Asp Thr Pro Tyr Leu Leu Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly  
 530 535 540

Lys Leu Phe Asn Lys Ser Lys Met Lys Leu Thr Phe Glu Gln Val Tyr  
 545 550 555 560

Ser Asp Cys Lys Lys Asn Arg Gly Thr Tyr Gly Thr Leu His Leu Gln  
 565 570 575

Asn Ser Phe Asn Ile Ser Glu His Leu Asn Ile Asn Glu His Thr Gly  
 580 585 590

Ser Ile Ser Ser Glu Leu Glu Ser Leu Lys Val Asn Leu Asn Ile Phe  
 595 600 605

Leu Leu Gly Ala Ala Gly Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys  
 610 615 620

Gly Ile Asp Arg Met Asn Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys  
 625 630 635 640

Ser Pro Ala Gly Val Asn Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala  
 645 650 655

Lys Ala Asn Ser Leu Pro Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg  
 660 665 670

Asp Ala Gln Thr Ile Lys Thr Ile His Gln Gln Arg Val Leu Pro Ile  
 675 680 685

Glu Gln Ser Leu Ser Thr Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg  
 690 695 700

Thr Gly Asn Gly Leu Leu Glu Arg Val Thr Arg Ile Leu Ala Ser Leu  
 705 710 715 720

Asp Phe Ala Gln Asn Phe Ile Thr Asn Asn Thr Ser Ser Val Ile Ile  
 725 730 735

## Untitled.ST25.txt

Glu Glu Thr Lys Lys Tyr Gly Arg Thr Ile Ile Gly Tyr Phe Glu His  
740 745 750

Tyr Leu Gln Trp Ile Glu Phe Ser Ile Ser Glu Lys Val Ala Ser Cys  
755 760 765

Lys Pro Val Ala Thr Ala Leu Asp Thr Ala Val Asp Val Phe Leu Cys  
770 775 780

Ser Tyr Ile Ile Asp Pro Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys  
785 790 795 800

Ala Thr Val Phe Leu Leu Pro Ala Leu Ile Phe Ala Val Lys Leu Ala  
805 810 815

Lys Tyr Tyr Arg Arg Met Asp Ser Glu Asp Val Tyr Asp Asp Val Glu  
820 825 830

Thr Ile Pro Met Lys Asn Met Glu Asn Gly Asn Asn Gly Tyr His Lys  
835 840 845

Asp His Val Tyr Gly Ile His Asn Pro Val Met Thr Ser Pro Ser Gln  
850 855 860

His  
865

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**